Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to demonstrate the non-inferior HAI immune response of quadrivalent recombinant influenza vaccine (RIV4) vs licensed Egg-Based Quadrivalent Influenza Vaccine (IIV4) for the 4 strains based on the egg-derived antigen in all participants aged 3 to 8 years and to describe the immunogenicity and safety profile of RIV4 compared to IIV4 in participants aged 3 to 8 years.


Clinical Trial Description

Participants will be enrolled on the day of their first vaccination to receive 1 or 2 doses 28 days apart of either RIV4 or IIV4; depending on if they were previously vaccinated against influenza or previously unvaccinated against influenza, respectively; and will be followed for 6 months after the last vaccination. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05513391
Study type Interventional
Source Sanofi
Contact
Status Terminated
Phase Phase 3
Start date November 10, 2022
Completion date October 3, 2023